MyMedR

Bone marrow-derived mesenchymal stem cells: A promising therapeutic option for the treatment of diabetic foot ulcers

Dama G, Du J, Zhu X, Liu Y, Lin J

Diabetes Res Clin Pract, 2023 Jan;195:110201.

PMID: 36493913 DOI: 10.1016/j.diabres.2022.110201

Chronic wounds fail to heal through the three normal stages of healing (inflammatory, proliferative, and remodelling), resulting in a chronic tissue injury that is not repaired within the average time limit. Patients suffering from type 1 and type 2 diabetes are prone to develop diabetic foot ulcers (DFUs), which commonly develop into chronic wounds that are non treatable with conventional therapies. DFU develops due to various risk factors, such as peripheral neuropathy, peripheral vascular disease, arterial insufficiency, foot deformities, trauma and impaired resistance to infection. DFUs have gradually become a major problem in the health care system worldwide. In this review, we not only focus on the pathogenesis of DFU but also comprehensively summarize the outcomes of preclinical and clinical studies thus far and the potential therapeutic mechanism of bone marrow-derived mesenchymal stem cells (BMSCs) for the treatment of DFU. Based on the published results, BMSC transplantation can contribute to wound healing through growth factor secretion, anti-inflammation, differentiation into tissue-specific cells, neovascularization, re-epithelialization and angiogenesis in DFUs. Moreover, clinical trials showed that BMSC treatment in patients with diabetic ulcers improved ulcer healing and the ankle-brachial index, ameliorated pain scores, and enhanced claudication walking distances with no reported complications. In conclusion, although BMSC transplantation exhibits promising therapeutic potential in DFU treatment, additional studies should be performed to confirm their efficacy and long-term safety in DFU patients.

Matched MeSH terms: Bone Marrow/pathology

Fulltext Waldenstrom's macroglobulinaemia--a case report

Chin NS, Teh A, Lee MK

Med J Malaysia, 1989 Jun;44(2):167-70.

PMID: 2516603

A case of Waldenstrom's macroglobulinemia with classical findings of IgM paraproteinaemia and a typical lymphoplasmacytic marrow infiltrate is reported and the treatment of this patient outlined.

Matched MeSH terms: Bone Marrow/pathology*

Neuroblastoma in Malaysian children

Sinniah D, Choo M, Somasundram K

Med J Malaysia, 1979 Dec;34(2):149-53.

PMID: 548717

Matched MeSH terms: Bone Marrow/pathology*

The diagnosis of nutritional megaloblastic anaemia: the use of bone marrow biopsy

TASKER PW

Med J Malaya, 1957 Dec;12(2):395-405.

PMID: 13515870

Matched MeSH terms: Bone Marrow/pathology*

Frozen bone marrow trephine biopsy--a technical evaluation

Cheong SK, Lim YC

Malays J Pathol, 1990 Jun;12(1):51-6.

PMID: 1708844

The routine study of bone marrow trephine biopsies involves fixation, decalcification, paraffin-embedment, sectioning and staining. However, this process creates artifacts, produces shrinkage of tissue, consumes time and can result in sections of unsatisfactory cytological quality. It also renders the tissue unsuitable for enzyme-histochemical and immunohistochemical analyses. Frozen section of bone marrow without decalcification was evaluated as an alternative method for the study of bone marrow. This method was found to give sections with comparable cytological quality to that of paraffin-embedment, yielded sections for interpretation within 24 hours, and allowed enzyme-histochemical and immunohistochemical analyses to be applied successfully.

Matched MeSH terms: Bone Marrow/pathology*

Residual post-treatment rhabdomyosarcoma in bone marrow: A reminder of the continued importance of morphology

Abobarin-Aofolaju O, Kaumeyer B, Kahwash SB

Malays J Pathol, 2024 Aug;46(2):339-340.

PMID: 39207013

No abstract available.

Matched MeSH terms: Bone Marrow/pathology

Fulltext Childhood idiopathic myelofibrosis: a case report and review of literature

Noor-Fadzilah Z, Leong CF, Sabariah MN, Cheong SK

Malays J Pathol, 2009 Dec;31(2):129-32.

PMID: 20514856 MyJurnal

Idiopathic myelofibrosis occurs predominantly in older adults. It is very rarely seen in children. We describe a 3-year-old girl with Down's syndrome who presented with recurrent chest infections associated with anaemia and easy bruising. There was mild hepatosplenomegaly. Full blood picture revealed pancytopaenia with leucoerythroblastosis with absence of circulating blast cells. Repeated attempts at bone marrow aspiration and trephine biopsy were unsuccessful. A trephine biopsy from the tibia showed depressed myelopoiesis and erythropoiesis, megakaryocytes with atypical morphology and increased bone marrow reticulin fibres, findings compatible with idiopathic myelofibrosis. She was treated symptomatically as she was clinically stable. Review of the English literature online yielded 46 reported cases of childhood idiopathic myelofibrosis with variable outcome from spontaneous remission to an indolent course with shortened survival. 6 cases evolved to another malignancy. 5 cases were associated with Down's syndrome.

Matched MeSH terms: Bone Marrow/pathology*

Fulltext Disseminated tuberculosis masquerading primary myelodysplastic syndrome

Shaharir SS, Tumian NR, Yu Lin AB, Abdul Wahid SF

J Infect Dev Ctries, 2013 Mar;7(3):286-8.

PMID: 23493009 DOI: 10.3855/jidc.2691

Tuberculosis is notoriously known to be a great mimicker of other diseases and may cause various haematologic abnormalities, especially with marrow involvement. A 61-year-old man who presented with right empyema and pancytopenia was diagnosed to have disseminated tuberculosis supported by the presence of caseating granuloma with Langhan's giant cells in the marrow and demonstration of acid-fast bacilli in the pleural fluid. Trilineage dysplasia from marrow aspirate was initially attributed to be reactive to the infection. A cytogenetic study was repeated after he showed poor response to a year of anti-tuberculosis treatment. The underlying primary myelodysplastic syndrome was unmasked when his cytogenetics showed trisomy 8. This case report has demonstrated the various haematological manifestations of tuberculosis and highlighted the importance of cytogenetic study in differentiating between primary and secondary myelodysplastic marrow changes.

Matched MeSH terms: Bone Marrow/pathology

Fulltext A case of kala-azar diagnosed by bone marrow aspiration

Hamidah NH, Cheong SK, Abu Hassan J

Malays J Pathol, 1995 Jun;17(1):39-41.

PMID: 8907004

A 35-year-old man from Bangladesh, who had been in Malaysia for approximately a year, was extensively investigated for more than two months in a state hospital for pyrexia with hepatosplenomegaly. However, no obvious cause of his illness was found. He was treated with multiple antibiotics with no resolution of pyrexia and hepatosplenomegaly. He was later referred to the Haematology Unit, Universiti Kebangsaan Malaysia for further assessment as a case of lymphoma. On carefully reviewing his bone marrow aspirate smears, the diagnosis of leishmaniasis (kala-azar) was finally made. The patient responded to treatment with pentamidine.

Matched MeSH terms: Bone Marrow/pathology*

Fulltext Myelosclerosis associated with systemic lupus erythematosus in patients in West Malaysia

Lau KS, White JC

J Clin Pathol, 1969 Jul;22(4):433-8.

PMID: 4183835 DOI: 10.1136/jcp.22.4.433

Three cases of myelosclerosis associated with systemic lupus erythematosus are described. The probable role of systemic lupus erythematosus in the initiation of myelonecrosis and subsequent myelosclerosis is discussed.

Matched MeSH terms: Bone Marrow/pathology*

Severe thalassaemia intermedia: clinical problems in the absence of hypertransfusion

Mohamed N, Jackson N

Blood Rev, 1998 Sep;12(3):163-70.

PMID: 9745886

In many of the parts of the world where thalassaemia is common, the blood supply is inadequate or unsafe, and desferrioxamine is too expensive for routine use. We classify some patients as having 'severe thalassaemia intermedia', i.e. those with moderately severe thalassaemia who can survive without regular transfusions, but who are at risk of many complications which are reviewed here. These include bone deformity and fractures, extramedullary haemopoietic tumours, leg ulcers, autoimmune haemolysis and, especially after splenectomy, thromboembolism and infection. An increase in the quality and safety of the blood supply, and a cheaper and/or oral iron chelator, would enable more of these patients to be treated as thalassaemia major and have improved survival and quality of life.

Matched MeSH terms: Bone Marrow/pathology

Systematic review of pre-clinical chronic myeloid leukaemia

Kuan JW, Su AT, Leong CF, Osato M, Sashida G

Int J Hematol, 2018 Nov;108(5):465-484.

PMID: 30218276 DOI: 10.1007/s12185-018-2528-x

BACKGROUND: Studies of a provisional entity pre-clinical chronic myeloid leukaemia (CML), which precedes chronic phase (CP) without leucocytosis or blood/marrow feature of CML CP, has been increasing.

OBJECTIVE: To perform a systematic review of pre-clinical CML and analysis the data relevant to disease progression to CML CP.

METHOD: We performed a literature search on 16 July 2017 using EBSCOhost Research Databases interface and Western Pacific Region Index Medicus. Two authors selected the studies, extracted the data and evaluated the quality of studies using an 8-item tool, independently. The outcomes were percentage of Philadelphia chromosome in the number of metaphases examined (Ph%), correlation between Ph% and blood count and time progress to CML.

RESULT: Our initial search returned 4770 studies. A total of 10 studies with a total 17 subjects were included. The lowest Ph%, which eventually progresses to CML, was 10%. Absolute basophil count seemed to correlate better with Ph% compared to total white cell and absolute eosinophil count. The time from the first documented pre-clinical CML to CML ranged from 12 to 48 months. The overall quality of the included studies was average.

CONCLUSION: This is the first systematic review on pre-clinical CML. This entity requires additional large-scale studies.

Matched MeSH terms: Bone Marrow/pathology

Fulltext Acute toxicity study of zerumbone-loaded nanostructured lipid carrier on BALB/c mice model

Rahman HS, Rasedee A, Othman HH, Chartrand MS, Namvar F, Yeap SK, et al.

Biomed Res Int, 2014;2014:563930.

PMID: 25276798 DOI: 10.1155/2014/563930

Zerumbone- (ZER-) loaded nanostructure lipid carrier (NLC) (ZER-NLC) prepared for its antileukemia effect in vitro was evaluated for its toxicological effects by observing changes in the liver, kidney, spleen, lung, heart, and brain tissues, serum biochemical parameters, total haemogram, and bone marrow stem cells. The acute toxicity study for ZER-NLC was conducted by orally treating BALB/c mice with a single dose with either water, olive oil, ZER, NLC, or ZER-NLC for 14 days. The animals were observed for clinical and behavioral abnormalities, toxicological symptoms, feed consumption, and gross appearance. The liver, kidney, heart, lung, spleen, and brain tissues were assessed histologically. Total haemogram was counted by hemocytometry and microhematocrit reader. Bone marrow examination in terms of cellular morphology was done by Wright staining with bone marrow smear. Furthermore, serum biochemical parameters were determined spectrophotometrically. Grossly all treated mice, their investigated tissues, serum biochemical parameters, total haemogram, and bone marrow were normal. At oral doses of 100 and 200 mg/kg ZER-NLC there was no sign of toxicity or mortality in BALB/c mice. This study suggests that the 50% lethal dose (LD50) of ZER-NLC is higher than 200 mg/kg, thus, safe by oral administration.

Matched MeSH terms: Bone Marrow/pathology

Approaches to deriving Schwann cells from human bone marrow for neural tube regeneration in a clinical setting

Hidayah HN, Mazzre M, Ng AM, Ruszymah BH, Shalimar A

Med J Malaysia, 2008 Jul;63 Suppl A:39-40.

PMID: 19024973

Bone marrow derived Mesenchymal stem cells (MSCs) were evaluated as an alternative source for tissue engineering of peripheral nerves. Human MSCs were subjected to a series of treatment with a reducing agent, retinoic acid and a combination of trophic factors. This treated MSCs differentiated into Schwann cells were characterized in vitro via flow cytometry analysis and immunocytochemically. In contrast to untreated MSCs, differentiated MSCs expressed Schwann cell markers in vitro, as we confirmed by flow cytometry analysis and immunocytochemically. These results suggest that human MSCs can be induced to be a substitute for Schwann cells that may be applied for nerve regeneration since it is difficult to grow Schwann cells in vitro.

Matched MeSH terms: Bone Marrow/pathology*

TEL-AML1 frequency in multi-ethnic Malaysian pediatric acute lymphoblastic leukemia

Gill HK, Keoh TS, Dhaliwal JS, Moore S, Kim TS, Hassan R, et al.

Cancer Genet. Cytogenet., 2005 Jan 15;156(2):129-33.

PMID: 15642392

Eighty-eight multi-ethnic Malaysian pediatric acute lymphoblastic leukemia (ALL) patients were screened for the TEL-AML1 rearrangement by reverse transcription-polymerase chain reaction (RT-PCR). Fluorescence in situ hybridization (FISH) was used as an independent screen for 30 cases and to confirm RT-PCR positive cases. Seventeen patients, or 19%, were found to be t(12;21) positive. Ethnically the group comprised 12 Malays, 4 Chinese, and 1 Indian. All patients, including 1 with an unusual blast cell morphology who suffered an early relapse and death, were characteristic TEL-AML1 cases in cell count, age, ALL subset classification, and fusion transcript expressed. This study shows that in Malaysia, TEL-AML1 is found in the same distinct ALL subset and at a similar frequency as in other diverse childhood ALL cohorts.

Matched MeSH terms: Bone Marrow/pathology

Fulltext Bone marrow and peripheral blood changes in non-Hodgkin's lymphoma

Lim EJ, Peh SC

Singapore Med J, 2000 Jun;41(6):279-85.

PMID: 11109344

47 patients with non-Hodgkin's lymphoma (NHL) were studied retrospectively to determine their marrow and blood changes at diagnosis.

Matched MeSH terms: Bone Marrow/pathology*

GATA1 mutations in patients with down syndrome and acute megakaryoblastic leukaemia do not always confer a good prognosis

Ariffin H, Garcia JC, Daud SS, Ibrahim K, Aizah N, Ong GB, et al.

Pediatr Blood Cancer, 2009 Jul;53(1):108-11.

PMID: 19260099 DOI: 10.1002/pbc.21983

Children with Down syndrome and acute megakaryoblastic leukemia (DS-AMKL) have been shown to have increased sensitivity to cytarabine based chemotherapy. The excellent prognosis in patients with DS-AMKL may be due to mutations in the GATA1 gene leading to reduced expression of the enzyme cytidine deaminase. This leads to a decreased ability to convert cytarabine into its inactive metabolite, resulting in high intracellular concentration of this cytotoxic agent. We report two cases of DS-AMKL with GATA1 mutations who had poor outcome. These patients had high expression levels of cytidine deaminase mRNA transcripts. We speculate that other factors can affect overall outcome in patients with DS-AMKL irrespective of the presence of GATA1 mutations.

Matched MeSH terms: Bone Marrow/pathology

Autoimmune thrombocytopenia and neutropenia after autologous peripheral blood stem cell transplantation

Wahid FS, Cheong SK, Sivagengei K

Acta Haematol., 2002;107(4):237-8.

PMID: 12053154

Matched MeSH terms: Bone Marrow/pathology

Fulltext Ocular involvement in acute lymphoblastic leukaemia

Tan AK, Azman A, Hoe TS, Rohana T

Med J Malaysia, 1994 Dec;49(4):409-11.

PMID: 7674978

A six-year-old boy, a known case of acute lymphoblastic leukaemia (ALL) on remission since 1991 presented with leukocoria and poor vision of the left eye for two days' duration. Examination revealed endophthalmitis in the left eye with raised intraocular pressure. Anterior chamber paracentesis with vitreous biopsy confirmed a diagnosis of ocular involvement. Further investigation revealed that he also had bone marrow and central nervous system relapse. Clinical manifestation and treatment modalities of ocular involvement in leukaemia are discussed.

Matched MeSH terms: Bone Marrow/pathology

Fulltext Acute leukemia in Malaysian children

Sinniah D, White JC, Omar A, Chua CP

Cancer, 1978 Oct;42(4):1970-5.

PMID: 280417 DOI: 10.1002/1097-0142%28197810%2942%3A4<1970%3A%3AAID-

A review of acute childhood leukemia in the University Hospital, Kuala Lumpur reveals no significant differences in either the epidemiological or clinical features between Malaysian and Caucasian children. BCG does not appear to have conferred any protection against the occurrence of leukemia. With the introduction of total therapy 4 of 10 patients with good prognostic features and 3 of 15 patients with poor prognostic features have survived 3 years. Prognosis appears to correlate with adopted clinical criteria.

Matched MeSH terms: Bone Marrow/pathology

Displaying publications 1 - 20 of 25 in total